Extended reality-enhanced behavioral activation offers a promising augmentation to traditional therapy for major depressive disorder, potentially overcoming accessibility barriers without compromising treatment efficacy, as demonstrated in a new randomized controlled trial.

As major depressive disorder (MDD) prevalence rises globally, innovative treatments like virtual reality (VR) offer new avenues for overcoming the traditional barriers to effective therapy. The study, published in JMIR Mental Health, evaluates the feasibility and clinical efficacy of an XR-enhanced behavioral activation (XR-BA) approach compared with traditional behavioral activation (BA), delivered via telehealth, in managing symptoms of MDD.

The randomized controlled trial included 26 patients diagnosed with MDD, split into two groups. One group received traditional BA via telehealth, while the other group participated in XR-BA using the Meta Quest 2 VR headset to simulate pleasant or mastery activities. The primary outcome was measured using the Patient Health Questionnaire (PHQ)–9.

Both groups showed significant reductions in PHQ-9 scores, indicating improvements in depressive symptoms. There were no significant differences in efficacy between the XR-BA and traditional BA groups, suggesting that XR-BA is a viable alternative to traditional methods. No adverse effects were reported, and dropout rates were similar between groups, underscoring the safety and feasibility of XR-BA.

"Extended reality-enhanced behavioral activation offers a promising augmentation to traditional therapy for major depressive disorder, potentially overcoming accessibility barriers without compromising treatment efficacy, as demonstrated in this randomized controlled trial," concluded the researchers. 

Some authors disclosed financial ties to entities with an interest in the research, including employment, consultancies, and stock ownership.